(Q36969021)

17 August 2017

1 reference

title

RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases (English)

1 reference

17 August 2017

cardiovascular disease

1 reference

Hidenori Koyama

1

1 reference

17 August 2017

Hiroshi Yamamoto

series ordinal

2

1 reference

17 August 2017

Yoshiki Nishizawa

series ordinal

3

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

17 August 2017

1 reference

17 August 2017

13

1 reference

17 August 2017

11-12

1 reference

17 August 2017

625-635

1 reference

https://scigraph.springernature.com/pub.10.2119/2007-00087.koyama

17 August 2017

0 references

cites work

Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

C-Reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Understanding RAGE, the receptor for advanced glycation end products

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE)

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Regulation of monocyte migration by amphoterin (HMGB1).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Central role of RAGE-dependent neointimal expansion in arterial restenosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Series introduction: multiligand receptors and human disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Atherosclerosis — An Inflammatory Disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of dia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Soluble receptor for advanced glycation end products in patients with decreased renal function.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Development of an ELISA for esRAGE and its application to type 1 diabetic patients

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Splice variants of the receptor for advanced glycosylation end products (RAGE) in human brain

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Enhanced expression of receptor for advanced glycation end products in chronic kidney disease

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Tissue-specific expression patterns of the RAGE receptor and its soluble forms—a result of regulated alternative splicing?

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

Pregnancy-Associated Plasma Protein A and Soluble Receptor for Advanced Glycation End Products after Kidney Transplantation

4 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2017106

N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins

4 December 2018

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

Effect of diabetes mellitus on formation of coronary collateral vessels

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of the BARI study. Balloon Angioplasty Revascularization Investigation

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

Blockade of RAGE suppresses alloimmune reactions in vitro and delays allograft rejection in murine heart transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

Soluble Levels of Receptor for Advanced Glycation Endproducts (sRAGE) and Coronary Artery Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

Soluble RAGE in type 2 diabetes: Association with oxidative stress

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

Plasma sRAGE is independently associated with urinary albumin excretion in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

Combination Therapy with the Advanced Glycation End Product Cross-Link Breaker, Alagebrium, and Angiotensin Converting Enzyme Inhibitors in Diabetes: Synergy or Redundancy?

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2119%2F2007-00087.KOYAMA

Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17932553

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17932553

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2119/2007-00087.KOYAMA

1 reference

Dimensions Publication ID

17 August 2017

0 references

1 reference

17 August 2017

1 reference